Smith & Nephew Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Los beneficios de Smith & Nephew han disminuido a una tasa media anual de -18.9%, mientras que en la industria Medical Equipment los beneficios disminuyeron en un 5.9% anualmente. Los ingresos han ido creciendo a una tasa media de 2.4% al año. La rentabilidad financiera de Smith & Nephew es de 5%, y sus márgenes netos son de 4.7%.

Información clave

-18.9%

Tasa de crecimiento de los beneficios

-19.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	-9.5%
Tasa de crecimiento de los ingresos	2.4%
Rentabilidad financiera	5.0%
Margen neto	4.7%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 11

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Aug 19

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Jul 17

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Jun 11

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

May 09

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Apr 09

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

Feb 09

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

Nov 21

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Nov 08

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Oct 26

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well

Aug 11

There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital

Jul 28

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price

Jun 26

Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

Apr 29

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Safely

Mar 26

Earnings Beat: Smith & Nephew plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 24

Smith & Nephew's (LON:SN.) Returns On Capital Not Reflecting Well On The Business

Jan 25

Are Investors Undervaluing Smith & Nephew plc (LON:SN.) By 30%?

Dec 02

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Smith & Nephew. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:SN. Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	5,549	263	2,890	320
30 Sep 23	5,449	241	2,816	324
01 Jul 23	5,349	218	2,741	327
01 Apr 23	5,282	221	2,718	331
31 Dec 22	5,215	223	2,695	335
30 Sep 22	5,214	360	2,680	344
02 Jul 22	5,213	496	2,665	352
02 Apr 22	5,213	510	2,651	351
31 Dec 21	5,212	524	2,637	349
30 Sep 21	5,168	539	2,607	340
03 Jul 21	5,124	553	2,576	330
03 Apr 21	4,842	501	2,508	319
31 Dec 20	4,560	448	2,439	307
30 Sep 20	4,624	420	2,470	304
27 Jun 20	4,688	391	2,501	301
27 Mar 20	4,913	496	2,518	297
31 Dec 19	5,138	600	2,534	292
30 Sep 19	5,044	649	2,449	281
29 Jun 19	4,949	698	2,364	269
29 Mar 19	4,927	681	2,374	258
31 Dec 18	4,904	663	2,384	246
30 Sep 18	4,887	690	2,450	239
30 Jun 18	4,869	717	2,496	232
31 Mar 18	4,817	742	2,453	228
31 Dec 17	4,765	767	2,419	223
30 Sep 17	4,721	817	2,346	224
01 Jul 17	4,677	867	2,282	224
01 Apr 17	4,673	826	2,269	227
31 Dec 16	4,669	784	2,255	230
30 Sep 16	4,680	570	2,515	228
02 Jul 16	4,690	356	2,393	225
02 Apr 16	4,662	383	2,363	224
31 Dec 15	4,634	410	2,524	222
30 Sep 15	4,702	513	2,333	224
27 Jun 15	4,669	557	2,326	225
27 Mar 15	4,680	499	2,375	234
31 Dec 14	4,617	501	2,323	235
27 Sep 14	4,543	503	2,285	239
28 Jun 14	4,422	523	2,201	241
29 Mar 14	4,349	563	2,124	235
31 Dec 13	4,351	556	2,149	231
28 Sep 13	4,253	534	2,045	215
29 Jun 13	4,178	544	2,013	196

Ingresos de calidad: SN. tiene un gran one-off loss de $264.0M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio (4.7%) de SN. son superiores a los del año pasado (4.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de SN. han disminuido en un 18.9% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de SN. en el último año (17.9%) supera su media de 5 años (-18.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de SN. en el último año (17.9%) no superó al de la industria Medical Equipment 17.9%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de SN. (5%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Smith & Nephew Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS misses analyst expectations

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Full year 2022 earnings: EPS misses analyst expectations

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

First half 2022 earnings released

Recent updates

Smith & Nephew plc (LON:SN.) Not Flying Under The Radar

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Consensus EPS estimates fall by 21%

Final dividend of US$0.23 announced

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Full year 2023 earnings: EPS misses analyst expectations

Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Is Smith & Nephew (LON:SN.) Using Too Much Debt?

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.0% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price

Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Consensus EPS estimates increase by 10%

Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate

Now 22% undervalued

Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Insider recently bought UK£117k worth of stock

Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold UK£111k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)

We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt

High number of new directors

CEO & Director exercised options to buy UK£59k worth of stock.

Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Upcoming dividend of US$0.14 per share

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Chairman recently bought UK£59k worth of stock

These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well

Consensus EPS estimates fall by 17%

First half 2022 earnings released

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price

Smith & Nephew plc Announces Executive Changes

Desglose de ingresos y gastos
Beta